The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Athenex; Daiichi Sankyo; Exact Sciences; Genentech/Roche
Research Funding - Abbvie (Inst); Roche
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
 
Charles Geyer
No Relationships to Disclose
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; Novartis; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Speakers' Bureau - EPG Communication; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)
 
Mothaffar F. Rimawi
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech; Macrogenics; Novartis; Seagen
Research Funding - Genentech (Inst); Pfizer (Inst)
 
Sara A. Hurvitz
Stock and Other Ownership Interests - Ideal Implant (I); ROM Tech (I)
Honoraria - Daiichi Sankyo/Astra Zeneca
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - Novartis; Roche
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Kyowa Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; MSD; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Kyung Hae Jung
Consulting or Advisory Role - AstraZeneca; Bixink; Celgene; Eisai; Everest Medicine; Merck; Novartis; Roche; Takeda
 
Gustavo Werutsky
Honoraria - AstraZeneca/MedImmune; Libbs; Merck; Pfizer
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb Brazil (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis; Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech
 
Daniil Stroyakovskiy
Research Funding - Roche
 
Vanesa López-Valverde
Employment - Roche
Stock and Other Ownership Interests - Roche
Research Funding - Roche
 
Michael Davis
Employment - Genentech
Stock and Other Ownership Interests - Roche
Research Funding - Roche
 
Tanja Badovinac Crnjevic
Employment - Roche
Stock and Other Ownership Interests - Roche
Research Funding - Roche
 
Pablo Diego Pérez-Moreno
Employment - Genentech
Stock and Other Ownership Interests - Roche
Research Funding - Roche
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)